Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to “Neutral” at Chardan Capital

Chardan Capital cut shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a buy rating to a neutral rating in a research report released on Tuesday, Marketbeat Ratings reports. They currently have $5.00 price objective on the stock.

Several other equities research analysts also recently issued reports on EYPT. Royal Bank Of Canada reissued a “sector perform” rating and set a $5.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. Jefferies Financial Group reduced their target price on shares of Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a research note on Monday. Guggenheim reiterated a “buy” rating and set a $68.00 target price on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. Finally, Stifel Nicolaus began coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.11.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ EYPT opened at $5.40 on Tuesday. The business has a 50 day simple moving average of $12.71 and a 200 day simple moving average of $13.44. Eyepoint Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $19.11. The stock has a market cap of $465.53 million, a price-to-earnings ratio of -1.44 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. On average, analysts predict that Eyepoint Pharmaceuticals will post -3.6 EPS for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in Eyepoint Pharmaceuticals by 2,158.3% in the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock valued at $1,355,000 after purchasing an additional 100,447 shares in the last quarter. Commodore Capital LP bought a new stake in shares of Eyepoint Pharmaceuticals during the 1st quarter worth approximately $36,414,000. Simplify Asset Management Inc. boosted its holdings in shares of Eyepoint Pharmaceuticals by 314.9% in the 4th quarter. Simplify Asset Management Inc. now owns 375,264 shares of the company’s stock valued at $6,856,000 after buying an additional 284,824 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at approximately $3,869,000. Finally, Swiss National Bank bought a new position in shares of Eyepoint Pharmaceuticals in the first quarter valued at $1,900,000. Institutional investors own 99.41% of the company’s stock.

More Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Management has argued that the failed LUGANO Phase 3 trial may have been distorted by an anomalous group of nine patients—about 4% of participants—with vision loss unrelated to wet AMD. The company also highlighted favorable secondary endpoints and Duravyu’s potential durability advantages. Positive results from the upcoming LUCIA Phase 3 trial, expected in the fourth quarter of 2026, could help restore confidence in the program. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Neutral Sentiment: Unusually heavy options activity indicates elevated trading and hedging interest, but does not establish a clear directional signal for EYPT. Eyepoint Pharmaceuticals Sees Unusually Large Options Volume
• Negative Sentiment: EyePoint is facing a shareholder investigation by SueWallSt over potential securities-law claims. Such notices can add legal uncertainty and further weigh on investor sentiment. EYPT Shareholder Investigation
• Negative Sentiment: Analyst sentiment has deteriorated following the trial result. Chardan Capital lowered its rating to Neutral, while Royal Bank of Canada cut EyePoint to Sector Perform and set a $5 price target. HC Wainwright, Cantor Fitzgerald, and JPMorgan maintained neutral-equivalent ratings, and Jefferies reduced its expectations. The broad lack of bullish ratings limits near-term valuation support. Chardan Capital Rating
• Negative Sentiment: The LUGANO Phase 3 failure caused a sharp sell-off because Duravyu did not meet its primary endpoint against Eylea. Analysts continue to view the result as a substantial risk to EyePoint’s pipeline and valuation, despite management’s explanation and the pending LUCIA data. EyePoint: Still A Sell After Phase 3 Crash

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.